Metoprolol Succinate Extended-Release Tablets, USP, 50 mg, packaged in (a) 100-count bottle, NDC 68001-501-00; (b) 500-count bottle, NDC 68001-501-03. Manufactured by Alkem Laboratories Ltd., India. For BluePoint Laboratories
Published February 22, 2023 · Recall initiated: January 11, 2023
Summary
FDA records drug Class II recall D-0269-2023, published February 22, 2023 and initiated January 11, 2023. Recalling firm: Amerisource Health Services LLC; Status: Terminated; Reported quantity: (a) 6670 100-count (b) 2666 500-count bottles; Lot: Lots: (a) 21143211, EXP 03/31/2023; (b) 21143185, 21143193, EXP 02/28/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Dissolution Specifications: This recall is being initiated in support of the recall by the manufacturer which included lots that were packaged for BluePoint Laboratories.
What to do
Voluntary: Firm initiated · Letter
Get an email if METOPROLOL SUCCINATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- METOPROLOL SUCCINATE
- Manufacturer
- Amerisource Health Services LLC
- Distributor
- Nationwide USA
- UPC
- 0368001503006
- Lot
- Lots: (a) 21143211, EXP 03/31/2023; (b) 21143185, 21143193, EXP 02/28/2023
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAAscend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by:May 20, 2026
- FDAMetoprolol Succinate Extended-Release Tablets, USP, 25 mg, Packaged in a) 100-count bottle, NDC 70010-780-01;July 9, 2025
- FDAThiamine Hydrochloride 3000 mg/30 mL (100mg/mL), Riboflavin 30 mg/30 mL (1mg/mL) Injection, FOR INTRAMUSCULARFebruary 22, 2023
- FDANew & Improved Blue Gel Anesthetic, to reduce pain and swelling during pain sensitive procedures, 1 oz bottle,February 22, 2023
- FDAMetoprolol Succinate Extended-Release Tablets, USP 50 mg, Rx Only, 100 Tablets per bottle, Manufactured by:February 1, 2023
- FDAMetoprolol Succinate Extended-Release Tablets, USP 25 mg, Rx Only, 100 Tablets per bottle, Manufactured by:February 1, 2023
Questions about this recall
Was Metoprolol Succinate Extended-Release Tablets, USP, 50 mg, packaged in (a) 100-count bottle, NDC 68001-501-00; (b) 500-count bottle, NDC 68001-501-03. Manufactured by Alkem Laboratories Ltd., India. For BluePoint Laboratories recalled?
Yes. FDA published recall D-0269-2023 on February 22, 2023. Reported hazard: Failed Dissolution Specifications: This recall is being initiated in support of the recall by the manufacturer which included lots that were packaged for BluePoint Laboratories.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: METOPROLOL SUCCINATE. UPC: 0368001503006.